View a Chinese translation of this page here
The scope of the European Journal of Hospital Pharmacy (EJHP) is broad and of interest to pharmacists and pharmaceutical scientists, as well as related disciplines of specific relevance to hospital pharmacy. The journal is of direct relevance to those involved in hospital pharmacy, as well as those involved with academic research, clinical, technical and social pharmacy, pharmaco-epidemiology and pharmaco-economics. The emphasis is on high quality content that augments the knowledge and practice of hospital pharmacists.
The print circulation exceeds 17,000 copies to hospital pharmacists in Europe. However, readership and authorship from other, non-European countries is encouraged. EJHP receives submissions from over 40 countries, many of which are from authors based outside Europe (including the USA, Asia, the Middle East and Africa). Readership of the online edition is global.
The journal publishes both professional and research content. In all cases the emphasis will be on quality, originality and the contribution of articles relevant to hospital pharmacists and their colleagues. Papers are considered on the basis that they are submitted solely to this journal and do not duplicate material already published, or submitted, elsewhere. In cases of doubt, and whenever material from the same study/dataset has been published elsewhere, please mention this to the editor in your cover letter, and explain the relationship between the manuscripts and how they differ. All manuscripts submitted to EJHP will be subjected to a rigorous peer review process.
The Editor has a policy of encouraging first time authors to achieve a standard of writing that is suitable for publication in the journal and support will be given to achieve this. First time authors are asked to either contact the firstname.lastname@example.org when considering submitting a manuscript, or state that fact in their cover letter.
For guidelines on submission and editorial policies for European Journal of Hospital Pharmacy please refer to the BMJ Author Hub. Here you will find information on planning your research through to submitting and promoting your research.
Article types and word counts
Full papers must present important, substantial new material and should be of direct relevance to clinical practise or important contributions to theoretical frameworks. Original articles should not exceed 3000 words plus references; articles that exceed this word limit may need to be returned for revision before peer review. Additional data may be presented as supplementary information, which will be published online only should the article be accepted (this can be in any format: text, tables, images, videos, etc.). If you are not a native English speaker there is a professional editing service now available. Original articles should be presented in sections:
No more than 250 words, summarising the problem being considered, how the study was performed, the salient results and the principal conclusions under subheadings ‘Objectives’, ‘Methods’, ‘Results’, and ‘Conclusions’.
Authors may also submit a version of their abstract in their local language, for publication online only. This should be uploaded as a separate file and labelled as ‘Abstract in local language’. The text should match the English version as closely as possible. Note that this version of the abstract will not be copyedited or typeset, and will be published online in the format provided by the author as supplementary information.
A minimum of 5 are required. These should be presented beneath the abstract and in the box provided in the online submission process.
Brief description of the background that led to the study (current results and conclusions should not be included).
Details relevant to the conduct of the study. Wherever possible give numbers of subjects studied (not percentages alone). Statistical methods should be clearly explained at the end of this section.
Undue repetition in text and tables should be avoided. Comment on validity and significance of results is appropriate but broader discussion of their implication is restricted to the next section. Subheadings that aid clarity of presentation within this and the previous section are encouraged.
The nature and findings of the study are placed in context of other relevant published data. Caveats to the study should be discussed. Avoid undue extrapolation from the study topic.
Acknowledgments and affiliations
Individuals with direct involvement in the study but not included in authorship may be acknowledged. The source of financial support and industry affiliations of all those involved must be stated.
Should not exceed 30.
Please see References for further style guidance.
Figures and tables
Maximum of 6 tables and/or figures. As there are no charges for colour figure reproduction, authors are encouraged to supply figures and illustrations in full colour.
Please see Figures/illustrations and Tables for further style guidance.
Units of measurement
Measurements of length, height, weight, and volume should be reported in metric units (metre, kilogram, or litre) or their decimal multiples. Temperatures should be given in degrees Celsius. Blood pressures should be given in millimetres of mercury. All haematological and clinical chemistry measurements should be reported in the metric system in terms of the International System of Units (SI). The symbol L for litre is recommended in order to avoid the risk of confusion between the letter l and the number 1. Percentages should normally be presented as whole numbers.
Abbreviations and symbols
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement.
Where applicable, articles should include trial registration: registry and number (for clinical trials and, if available, for observational studies and systematic reviews). Please refer to our policy for trial registration.
Research reporting guidelines
BMJ requires compliance to the following reporting guidelines. Please upload the relevant completed checklist for your study type with your submission, and label it “Research checklist”. If no relevant checklist is available for your study type, this can be indicated on the submission form.
Required for all randomised controlled trials
Required for all systematic reviews
Required for all economic evaluations
Required for all diagnostic research papers
Required for all observational studies
Required for all quality improvement studies
Guidance and forms are available from EQUATOR.
When you submit your manuscript we will ask you for ‘key messages’. This is a short summary explaining what your article adds to the literature. It should be divided into two sections:
- What is already known on this subject – In two or three single sentence bullet points please summarise the state of scientific knowledge on this subject before you did your study and why this study needed to be done. Be clear and specific, not vague.
- What this study adds – In one or two single sentence bullet points give a simple answer to the question “What do we now know as a result of this study that we did not know before?” Be brief, succinct, specific, and accurate.
The journal welcomes systematic reviews with or without meta-analyses according to PRISMA guidelines. Authors may wish to seek the advice of the email@example.com in advance.
Word count: up to 3000 words
Abstract: up to 250 words
Tables/illustrations: maximum of 6
References: up to 50
The format is identical to that of an original article (see above) and should include an Abstract, Keywords, Introduction, Methods, Results and Discussion.
Word count: up to 1500 words.
Abstract: up to 150 words.
Tables/illustrations: maximum 1 table and/or figure.
References: up to 15
The aim of an Editorial is to stimulate thought (often with more questions than answers) rather than review the subject exhaustively. Editorials are often commissioned and linked to one or more articles published in the same issue. Personal opinion and comment are perfectly legitimate since the Editorial is not anonymous, though of course such opinion needs to be reasonable and backed up by appropriate evidence.
Word count: up to 1500 words
Tables/illustrations: maximum of 2 tables and/or figures
References: up to 30
Letter to the Editor
The objective of a letter is to provide a platform for discussion and dialogue between readers and the EJHP. Readers are encouraged to submit items for discussion which would be of particular interest to hospital pharmacists, as well as to submit feedback on a topic in a previous issue. This article can be in the style of a letter-to-the-editor, and can either be opinion based or can focus on the factual background of a previously published topic.
Word count: up to 500 words
Tables/illustrations: maximum of 1
References: up to 5
Readers have the opportunity to comment directly and immediately on any article published online. E-letters should be submitted electronically via the website. Contributors should go to the article in question and click on the ‘Responses’ tab to complete the online form.
Hands on medicines information
This section aims to present clinical queries arising from medicines information practice. These should be complex or unusual queries that would be of interest to other hospital pharmacists that may come across similar cases in their clinical practice.
The submission should present a clearly defined clinical question and answer, which should be supported with scientific evidence. The inclusion of patient-specific information and an outcome assessment is strongly encouraged.
The article should be structured as:
Summary of up to 150 words
Introduction, including the case presentation and any clinical or background information relevant to the query
Recommended answer, including the problem-solving approach used (if applicable)
Outcome and discussion
Key message/learning outcome of one sentence
Word count: up to 1500 words
Tables/illustrations: maximum 1 table and/or figure
References: up to 10
A case report should be a detailed narrative that describes for pharmaceutical, medical, scientific or educational purposes a medication problem experienced by one or several patients and focused on pharmaceutical aspects in the medication process with (potential) harm to the patient (critical incidence) or proven specific benefit/result. The case could also be of a medication error that may have wider interest. A pharmacist should be involved in the process and the contribution and interest for pharmacists clearly stated.
The case report must be submitted in the form of the standard EJHP template.
Case reports are also required to fulfil certain criteria:
- They should add to the clinical and/or pharmaceutical knowledge, so should not be about a common occurrence.
- They should be set in the context of the wider literature. In particular, authors should check whether the problem has already been discussed or reported elsewhere.
- For patient-related reports, signed permission for publication must be obtained from the patient(s) concerned according to BMJ’s usual patient consent guidelines.
Peer review process
The journal uses a single blind peer review process. At least two external reviewer reports are usually be obtained before an original article or review is accepted for publication. Manuscripts authored by a member of a journal’s editorial team are independently peer reviewed; an editor will have no input or influence on the peer review process or publication decision for their own article. Letters to the editor and educational items (e.g. case reports) may only be reviewed internally by members of the editorial team. Editorials written by the journal’s editor and news items do not undergo peer review. A provenance and peer review statement is included on each published article.
Journals from BMJ are willing to consider publishing supplements to regular issues. Supplement proposals may be made at the request of:
- The journal editor, an editorial board member or a learned society may wish to organise a meeting, sponsorship may be sought and the proceedings published as a supplement.
- The journal editor, editorial board member or learned society may wish to commission a supplement on a particular theme or topic. Again, sponsorship may be sought.
- BMJ itself may have proposals for supplements where sponsorship may be necessary.
- A sponsoring organisation, often a pharmaceutical company or a charitable foundation, that wishes to arrange a meeting, the proceedings of which will be published as a supplement.
In all cases, it is vital that the journal’s integrity, independence and academic reputation is not compromised in any way.
For further information on criteria that must be fulfilled, download the supplement guidelines .
BMJ is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. iThenticate checks submissions against millions of published research papers, and billions of web content. Authors, researchers and freelancers can also use iThenticate to screen their work before submission by visiting www.ithenticate.com.